Literature DB >> 16000399

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk.

Antonius E van Herwaarden1, Els Wagenaar, Barbara Karnekamp, Gracia Merino, Johan W Jonker, Alfred H Schinkel.   

Abstract

The breast cancer resistance protein (BCRP/ABCG2) usually protects the body from a wide variety of environmental and dietary xenotoxins by reducing their net uptake from intestine and by increasing their hepatobiliary, intestinal and renal elimination. BCRP is also highly expressed in lactating mammary glands in mice, and this expression is conserved in cows and humans. As a result, BCRP substrates can be secreted into milk. We investigated whether different classes of dietary carcinogens are substrates of Bcrp1/BCRP and the implications for systemic exposure and breast milk contamination. Using polarized cell lines, we found that Bcrp1 transports the heterocyclic amines 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) and the potent human hepatocarcinogen aflatoxin B1, and decreases their cellular accumulation up to 10-fold. In vivo pharmacokinetic studies showed that [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin B1 plasma levels were substantially lower in wild-type compared with Bcrp1-/- mice, after both oral and intravenous administration, demonstrating that Bcrp1 restricts systemic exposure to these carcinogens. Moreover, Bcrp1 mediates transfer of [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin into milk, with 3.4+/-0.6, 2.6+/-0.3 and 3.8+/-0.5-fold higher milk to plasma ratios, respectively, in lactating wild-type versus Bcrp1-/- mice. We have thus identified Bcrp1/BCRP as one of the molecular mechanisms by which heterocyclic amines and aflatoxin are transferred into milk, thereby posing a health risk to breast-fed infants and dairy consumers. Paradoxically, Bcrp1/BCRP appears to have both protective and adverse roles with respect to exposure to dietary carcinogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000399     DOI: 10.1093/carcin/bgi176

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  31 in total

Review 1.  Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.

Authors:  Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 2.  ATP-binding cassette, subfamily G (ABCG family).

Authors:  Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pflugers Arch       Date:  2006-09-16       Impact factor: 3.657

Review 3.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

Review 4.  Interaction of Isoflavones with the BCRP/ABCG2 Drug Transporter.

Authors:  Kristin M Bircsak; Lauren M Aleksunes
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

5.  Regulation of the placental BCRP transporter by PPAR gamma.

Authors:  Yixin Lin; Kristin M Bircsak; Ludwik Gorczyca; Xia Wen; Lauren M Aleksunes
Journal:  J Biochem Mol Toxicol       Date:  2016-11-23       Impact factor: 3.642

6.  The anthelmintic triclabendazole and its metabolites inhibit the membrane transporter ABCG2/BCRP.

Authors:  Borja Barrera; Jon A Otero; Estefanía Egido; Julio G Prieto; Anna Seelig; Ana I Álvarez; Gracia Merino
Journal:  Antimicrob Agents Chemother       Date:  2012-04-16       Impact factor: 5.191

Review 7.  ABCG transporters: structure, substrate specificities and physiological roles : a brief overview.

Authors:  Saroj Velamakanni; Shen L Wei; Tavan Janvilisri; Hendrik W van Veen
Journal:  J Bioenerg Biomembr       Date:  2007-12       Impact factor: 2.945

Review 8.  Drug transporters in the human blood-placental barrier.

Authors:  Kirsi Vähäkangas; Päivi Myllynen
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

9.  Berry anthocyanins and anthocyanidins exhibit distinct affinities for the efflux transporters BCRP and MDR1.

Authors:  A Dreiseitel; B Oosterhuis; K V Vukman; P Schreier; A Oehme; S Locher; G Hajak; P G Sand
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

10.  Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

Authors:  Vibeke Andersen; Mette Ostergaard; Jane Christensen; Kim Overvad; Anne Tjønneland; Ulla Vogel
Journal:  BMC Cancer       Date:  2009-11-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.